Evaluation and Modification of a Shared Decision-Making Tool for Peanut Allergy Management

This study refined the decision aid ’s content to better reflect patients’ and caregivers’ lived experience.Recent FindingsCurrent standard of care for peanut allergy is avoidance, although peanut oral immunotherapy has been approved by the Food and Drug Administration for use in patients 4 –17 years old.SummaryAn advisory board of allergy therapy experts (n = 3) and patient advocates (n = 3) informed modifications to the decision aid. The revised tool underwent cognitive debriefing interviews (CDIs) among adolescents (12–17 years old) with peanut allergy and caregivers of patients 4–17 years old with peanut allergy to evaluate its relevance, understandability, and usefulne ss. The 20 CDI participants understood the information presented in the SDM tool and reported it was important and relevant. Some revisions were made based on participant feedback. Results support content validity of the Peanut Allergy Treatment SDM Tool.
Source: Current Allergy and Asthma Reports - Category: Allergy & Immunology Source Type: research